You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 17, 2025

Anacor Pharms Inc Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Anacor Pharms Inc
International Patents:126
US Patents:4
Tradenames:2
Ingredients:2
NDAs:2

Drugs and US Patents for Anacor Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Anacor Pharms Inc EUCRISA crisaborole OINTMENT;TOPICAL 207695-001 Dec 14, 2016 RX Yes Yes 8,168,614*PED ⤷  Try for Free Y ⤷  Try for Free
Anacor Pharms Inc EUCRISA crisaborole OINTMENT;TOPICAL 207695-001 Dec 14, 2016 RX Yes Yes 9,682,092*PED ⤷  Try for Free Y ⤷  Try for Free
Anacor Pharms Inc EUCRISA crisaborole OINTMENT;TOPICAL 207695-001 Dec 14, 2016 RX Yes Yes ⤷  Try for Free ⤷  Try for Free
Anacor Pharms Inc EUCRISA crisaborole OINTMENT;TOPICAL 207695-001 Dec 14, 2016 RX Yes Yes 8,039,451*PED ⤷  Try for Free Y ⤷  Try for Free
Anacor Pharms Inc KERYDIN tavaborole SOLUTION;TOPICAL 204427-001 Jul 7, 2014 DISCN Yes No ⤷  Try for Free ⤷  Try for Free
Anacor Pharms Inc EUCRISA crisaborole OINTMENT;TOPICAL 207695-001 Dec 14, 2016 RX Yes Yes 8,501,712*PED ⤷  Try for Free Y ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration
Paragraph IV (Patent) Challenges for ANACOR PHARMS INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Topical Solution 5% ➤ Subscribe 2018-07-09

Supplementary Protection Certificates for Anacor Pharms Inc Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2343304 20C1024 France ⤷  Try for Free PRODUCT NAME: CRISABOROLE, OPTIONNELLEMENT SOUS LA FORME D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE; REGISTRATION NO/DATE: EU/1/19/1421 20200401
2343304 301049 Netherlands ⤷  Try for Free PRODUCT NAME: CRISABOROLE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/19/1421 20200401
2343304 PA2020524 Lithuania ⤷  Try for Free PRODUCT NAME: KRISABOROLAS, PASIRINKTINAI FARMACINIU POZIURIU PRIIMTINOS DRUSKOS FORMOJE; REGISTRATION NO/DATE: EU/1/19/1421 20200327
2343304 2020/024 Ireland ⤷  Try for Free PRODUCT NAME: CRISABOROLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTRATION NO/DATE: EU/1/19/1421/001 EU/1/19/1421/004 20200327
2343304 122020000038 Germany ⤷  Try for Free PRODUCT NAME: CRISABOROL, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES DAVON; REGISTRATION NO/DATE: EU/1/19/1421 20200327
2343304 2090017-1 Sweden ⤷  Try for Free PRODUCT NAME: CRISABOROLE, OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALT; REG. NO/DATE: EU/1/19/1421 20200401
2343304 C 2020 030 Romania ⤷  Try for Free PRODUCT NAME: CRISABOROL SI SARURILE SALE FARMACEUTIC ACCEPTABILE FARMACEUTIC; NATIONAL AUTHORISATION NUMBER: EU/1/19/1421; DATE OF NATIONAL AUTHORISATION: 20200327; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/19/1421; DATE OF FIRST AUTHORISATION IN EEA: 20200327
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Pharmaceutical Competitive Landscape Analysis: Anacor Pharmaceuticals Inc – Market Position, Strengths & Strategic Insights

In the ever-evolving pharmaceutical industry, understanding the competitive landscape is crucial for success. Today, we're diving deep into Anacor Pharmaceuticals Inc., a company that has made significant waves in the sector. Let's explore their market position, strengths, and the strategic insights that have shaped their journey.

Anacor Pharmaceuticals: A Brief Overview

Anacor Pharmaceuticals, founded in 2002, quickly established itself as a biopharmaceutical company focused on discovering, developing, and commercializing novel small-molecule therapeutics derived from its boron chemistry platform[2]. This unique approach set Anacor apart in a crowded pharmaceutical landscape.

The Boron Chemistry Platform: Anacor's Secret Weapon

At the heart of Anacor's success lies its innovative boron chemistry platform. This technology allowed the company to develop a range of compounds with potential applications across various therapeutic areas. The platform's versatility became a key differentiator for Anacor in the competitive pharmaceutical market.

Market Position and Product Portfolio

Anacor's market position was primarily built on two key products:

  1. KERYDIN® (tavaborole): An FDA-approved topical solution for the treatment of onychomycosis of the toenails[6].

  2. Crisaborole: A promising anti-inflammatory compound for the treatment of mild-to-moderate atopic dermatitis[1].

KERYDIN: Anacor's First Approved Product

KERYDIN, approved by the FDA in July 2014, represented a significant milestone for Anacor. The product's success in the market for toenail fungus treatment helped establish Anacor's credibility and provided a steady revenue stream.

Crisaborole: The Pipeline Star

Crisaborole, Anacor's lead pipeline product, garnered significant attention from both the medical community and potential acquirers. Its potential as a first-line treatment for atopic dermatitis positioned Anacor as a valuable player in the dermatology market.

"We believe the acquisition of Anacor represents an attractive opportunity to address a significant unmet medical need for a large patient population with mild-to-moderate atopic dermatitis, which currently has few safe topical treatments available," said Albert Bourla, Group President of Pfizer's Global Innovative Pharma and Global Vaccines, Oncology and Consumer Healthcare Businesses[1].

Anacor's Strategic Strengths

Several key strengths contributed to Anacor's success and ultimately made it an attractive acquisition target:

1. Innovative Research Platform

Anacor's boron chemistry platform allowed for the development of novel compounds with unique properties. This innovation engine set Anacor apart from competitors and provided a pipeline of potential future products.

2. Focus on Unmet Medical Needs

By targeting areas with limited treatment options, such as atopic dermatitis, Anacor positioned itself to capture significant market share upon product approval.

3. Strong Intellectual Property Portfolio

Anacor's robust patent protection for its key products and technologies provided a competitive moat and enhanced its value proposition.

4. Strategic Partnerships

Collaborations with companies like Eli Lilly and GlaxoSmithKline demonstrated Anacor's ability to leverage its technology platform through strategic partnerships[6].

Financial Performance and Market Valuation

Anacor's financial performance reflected its transition from a research-focused company to one with commercial products. In 2015, the company reported:

  • Revenue range: $10 million to $50 million
  • Funding secured: $250 million[2]

These figures indicated Anacor's growing commercial potential and its ability to attract significant investment.

Market Valuation: A Testament to Potential

Anacor's market capitalization reached approximately $2.1 billion by early 2015[7]. This valuation reflected investor confidence in Anacor's pipeline, particularly the potential of crisaborole.

The Pfizer Acquisition: A Strategic Milestone

In May 2016, pharmaceutical giant Pfizer announced its intention to acquire Anacor for $5.2 billion, or $99.25 per share in cash[1]. This acquisition marked a significant milestone in Anacor's journey and validated its strategic approach.

Rationale Behind the Acquisition

Pfizer's decision to acquire Anacor was driven by several factors:

  1. Expansion of inflammation and immunology portfolio
  2. Near-term revenue growth potential
  3. Complementary fit with existing franchises
  4. Access to innovative technology platform

Impact on Pfizer's Strategy

The Anacor acquisition aligned with Pfizer's strategy to strengthen its innovative business segment. It provided Pfizer with:

  • A potential first-line treatment option for atopic dermatitis
  • Enhanced near-term revenue growth prospects
  • Strengthened position in inflammation and immunology

Competitive Landscape Analysis

To fully appreciate Anacor's position, it's essential to consider the broader competitive landscape in the dermatology and inflammation markets.

Key Competitors

  1. Regeneron Pharmaceuticals: Developer of dupilumab, a potential competitor to crisaborole[8].
  2. Other major pharmaceutical companies with dermatology portfolios, such as Johnson & Johnson and Novartis.

Competitive Advantages

Anacor's focus on topical treatments with a novel mechanism of action provided a unique positioning in the market. The potential for crisaborole to be a first-line treatment for atopic dermatitis gave Anacor a significant competitive edge.

Strategic Insights and Future Outlook

Anacor's journey offers several strategic insights for pharmaceutical companies:

1. Focus on Innovative Platforms

Anacor's success stemmed from its unique boron chemistry platform. Investing in innovative research platforms can provide a sustainable competitive advantage.

2. Target Unmet Medical Needs

By focusing on areas with limited treatment options, companies can capture significant market share and attract attention from larger pharmaceutical players.

3. Balance Pipeline and Commercial Products

Anacor's strategy of developing a commercial product (KERYDIN) while advancing its pipeline candidate (crisaborole) provided a balanced approach to growth and risk management.

4. Leverage Strategic Partnerships

Collaborations with larger pharmaceutical companies can provide valuable resources and validation for smaller biotech firms.

Lessons for the Pharmaceutical Industry

Anacor's story provides valuable lessons for other players in the pharmaceutical industry:

  1. Innovation is key: Novel approaches to drug discovery and development can set a company apart in a crowded market.

  2. Focus matters: Concentrating on specific therapeutic areas or technologies can lead to expertise and market leadership.

  3. Strategic positioning is crucial: Positioning products as potential first-line treatments can attract both patients and acquirers.

  4. Intellectual property is valuable: A strong patent portfolio can provide a competitive moat and increase company valuation.

Key Takeaways

  • Anacor Pharmaceuticals leveraged its innovative boron chemistry platform to develop novel therapeutics.
  • The company's focus on unmet medical needs in dermatology positioned it for success.
  • Anacor's lead product, crisaborole, played a crucial role in attracting Pfizer's $5.2 billion acquisition offer.
  • The company's strategy balanced pipeline development with commercialization of approved products.
  • Anacor's journey highlights the importance of innovation, focus, and strategic positioning in the pharmaceutical industry.

FAQs

  1. Q: What was Anacor Pharmaceuticals' primary focus? A: Anacor focused on discovering, developing, and commercializing novel small-molecule therapeutics derived from its boron chemistry platform, primarily in dermatology.

  2. Q: Why did Pfizer acquire Anacor Pharmaceuticals? A: Pfizer acquired Anacor to expand its inflammation and immunology portfolio, particularly gaining access to crisaborole, a potential first-line treatment for atopic dermatitis.

  3. Q: How did Anacor's boron chemistry platform contribute to its success? A: The boron chemistry platform allowed Anacor to develop unique compounds with novel properties, setting it apart from competitors and providing a pipeline of potential products.

  4. Q: What were Anacor's key products? A: Anacor's key products were KERYDIN, an FDA-approved treatment for toenail fungus, and crisaborole, a pipeline product for atopic dermatitis.

  5. Q: What lessons can other pharmaceutical companies learn from Anacor's journey? A: Key lessons include the importance of focusing on innovative platforms, targeting unmet medical needs, balancing pipeline and commercial products, and leveraging strategic partnerships.

Sources cited:

  1. https://www.pfizer.com/news/press-release/press-release-detail/pfizer_to_acquire_anacor
  2. https://leadiq.com/c/anacor-pharmaceuticals/5a1d8a9e2400002400646ff2
  3. https://www.pfizer.com/news/press-release/press-release-detail/pfizer_completes_acquisition_of_anacor
  4. https://www.investing.com/equities/anacor--pharmaceuticals
  5. https://www.thestreet.com/markets/strong-on-high-volume-anacor-pharmaceuticals-anac-13078484
  6. https://www.biospace.com/delving-into-pfizer-s-anacor-acquisition-strategy-and-its-impact-on-regeneron

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.